Terbutaline: profile and news

[an error occurred while processing this directive]

Other information

Indication
For the prevention of and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema; For the management of preterm labor

Pharmacology
Terbutaline is a relatively selective beta2-adrenergic bronchodilator. Terbutaline is indicated for the relief of bronchospasm associated with chronic obstructive pulmonary disease. The pharmacologic effects of beta adrenergic agonist drugs, including Terbutaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Mechanism Of Action
The pharmacologic effects of Terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Drug Category
Adrenergic beta-Agonists; Tocolytic Agents; Bronchodilator Agents; Sympathomimetic; ATC:R03AC03; ATC:R03CC03

Brand Names/Synonyms
Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; CHEMBANK743; KWD 2019; T2528; Terbutalin; Terbutalina [Dcit]; Terbutaline; Terbutaline Sulfate; Terbutalino [Inn-Spanish]; Terbutalinum [Inn-Latin]

Dosage Forms
METERED-DOSE (AEROSOL); POWDER; Tablets; IV Injection; Subcutaneous Injection

Absorption
Not Available

Interactions
Drug Interactions: The concomitant use of Terbutaline with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: Terbutaline should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline on the vascular system may be potentiated. Beta-Blockers: Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as Terbutaline, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. Diuretics: The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics.

Chemical IUPAC Name
5-(1-hydroxy-2-tert-butylamino-ethyl)benzene-1,3-diol

Chemical Formula
C12H19NO3

Half Life
5.5-5.9 hours

Drug Type
Approved Drug

# Accession No
APRD00589

CAS Registry Number
23031-25-6